Optimisation of takeaway delivery routes considering the mutual satisfactions of merchants and customers

2021 ◽  
Vol 162 ◽  
pp. 107728
Author(s):  
Ren Teng ◽  
Xu Hong-bo ◽  
Jin Kang-ning ◽  
Luo Tian-yu ◽  
Wang Ling ◽  
...  
Keyword(s):  
Biomolecules ◽  
2021 ◽  
Vol 11 (8) ◽  
pp. 1135
Author(s):  
Bhubanananda Sahu ◽  
Isha Chug ◽  
Hemant Khanna

The eye is at the forefront of developing therapies for genetic diseases. With the FDA approval of the first gene-therapy drug for a form of congenital blindness, numerous studies have been initiated to develop gene therapies for other forms of eye diseases. These examinations have revealed new information about the benefits as well as restrictions to using drug-delivery routes to the different parts of the eye. In this article, we will discuss a brief history of gene therapy and its importance to the eye and ocular delivery landscape that is currently being investigated, and provide insights into their advantages and disadvantages. Efficient delivery routes and vehicle are crucial for an effective, safe, and longer-lasting therapy.


2003 ◽  
Vol 1 (4) ◽  
pp. 254-259 ◽  
Author(s):  
Leonardo Kapural ◽  
Alexandra Szabova ◽  
Nagy A Mekhail

Toxins ◽  
2021 ◽  
Vol 13 (2) ◽  
pp. 77
Author(s):  
Andrew G. Lee ◽  
Shin-Hyo Lee ◽  
Minsu Jang ◽  
Sang Jae Lee ◽  
Hyun Jin Shin

The purpose of this study was to determine and compare the effects between injecting botulinum toxin A (BTX-A) transconjunctivally into the palpebral lobe and transcutaneously into the orbital lobe of the lacrimal gland in patients with epiphora due to lacrimal outflow obstruction. This randomized controlled study included 53 eyes of 31 patients with unilateral or bilateral epiphora. Patients were randomly allocated to receive an injection of BTX-A (3 units) either transconjunctivally (n = 15, 25 eyes) or transcutaneously (n = 16, 28 eyes). For objective assessments, the tear meniscus height and Schirmer’s I test with topical anesthesia were measured at baseline and after 2, 6, 12, and 24 weeks of follow-up. Subjective evaluations were performed using the Munk score. After BTX-A injection, patients in both groups experienced significant objective and subjective reductions in tearing at all follow-up times compared to pre-injection (success rate 86.8%), and the effect lasted for a mean duration of 5.63 months. The two delivery routes showed similar clinical effectiveness for a single injected dose of BTX-A. In conclusion, injecting BTX-A via either a transconjunctival or transcutaneous route helps to reduce normal tear production and results in significant improvements in the symptoms in patients with epiphora.


1994 ◽  
pp. 411-413 ◽  
Author(s):  
T. Nakajima ◽  
S. Ishihara ◽  
H. Motohashi ◽  
Y. Kitamura ◽  
Y. Nakajima ◽  
...  

Author(s):  
David Raba ◽  
Rafael D. Tordecilla ◽  
Pedro Copado ◽  
Angel A. Juan ◽  
Daniel Mount

Looking for an accurate and cost-effective solution to measure feed inventories, forecast the feed demand and allow feed suppliers to optimize inventories, production batches, and delivery routes.


Sign in / Sign up

Export Citation Format

Share Document